Tolerability and pharmacokinetics of single and multiple ascending doses of GS 5816, with or without food, in volunteers

Trial Profile

Tolerability and pharmacokinetics of single and multiple ascending doses of GS 5816, with or without food, in volunteers

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Feb 2017

At a glance

  • Drugs Velpatasvir (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 13 Feb 2017 Results preclinical and clinical pharmacokinetics, safety, tolerability, published in the Antimicrobial Agents and Chemotherapy
    • 05 May 2013 New trial record
    • 28 Apr 2013 Results for the single and multiple dose cohorts presented at the 48th Annual Meeting of the European Association for the Study of the Liver.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top